

Prostate Cancer

Suggested Reading List

Useful Web Sites

- for practice guideline summaries from Cancer Care Ontario:
www.cancercare.on.ca/index_practiceGuidelines.htm
- to review the National Cancer Institute's Physician Data Query on this disease site:
www.cancer.gov
- to view the American Society of Clinical Oncology website, visit www.asco.org
- to view guidelines/special articles from the American Society of Clinical Oncology visit:
www.jco.org/misc/specialarticles.shtml
- to view practice guidelines from the National Comprehensive Cancer Network, visit
www.nccn.org
- BC Cancer website: www.bccancer.bc.ca

1. Frydenberg M et al. Prostate cancer diagnosis and management. The Lancet, vol. 349, June 7, 1997, pp. 1681-1687.
2. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. The Lancet, Vol. 355, April 29, 2000, pp. 1491-1498.
3. Petrylak DP. Chemotherapy For Advanced Hormone Refractory Prostate Cancer. Urology 54 (Supplement 6A), December 1999, pp. 30-35.
4. Izawa JI et al. The role of angiogenesis in prostate and other urologic cancers: a review. CMAJ 2001; 164(5): 662-670.
5. Brundage M et al. Use of Sstrontium-89 in endocrine-refractory prostate cancer metastatic to bone. Cancer Prevention & Control 1998, 2(2), pp. 79-87, (CCO Practice Guidelines Initiative).
6. Tannock I et al. Chemotherapy with Mitoxantrone Plus Prednisone or Prednisone Alone for Symptomatic Hormone-Resistant Prostate Cancer: A Canadian Randomized Trial With Palliative End Points. J Clin Oncol, vol. 14, No 6 June 1996, pp. 1756-1764.
7. Logothtis CJ. Docetaxel in the Integrated Management of Prostate Cancer. Oncology vol. 16 no. 6, Suppl 6(June 2002).
8. Senzer NN. Prostate Cancer: Multimodality Approaches with Docetaxel. Semin Oncol 28 (suppl 15):77-85.
9. Oefelein MG et al. Skeletal Fractures Negatively Correlate with Overall Survival in Men with Prostate Cancer. The Journal of Urology vol. 168, 1005-1007, Sept. 2002.
10. Saad F et al. A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients with Hormone-Refractory Metastatic Prostate Carcinoma. JNCI 2002; 94:1458-68.
11. Pentylala SN et al. Prostate cancer: a comprehensive review. Medical Oncology 2000, 17:85-105.
12. Tannock IF et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (15): 1502-12, 2004. (TAX 327 study)
13. PJani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet 2003; 361: 1045-53.

Latest Revision May 2019